Background
==========

Quinolones and beta-lactams are widely used antibiotics for the treatment of bacterial infections and are also extensively used in the food-processing industry. Their wide use has triggered increased bacterial resistance worldwide \[[@B1]\]. Quinolone resistance and extended-spectrum beta-lactamase (ESBL) production are often associated in *Enterobacteriaceae*\[[@B1]\]. The prescription of quinolones may consequently select bacteria that are not only quinolone-resistant but also beta-lactam-resistant and vice versa. The biological mechanisms of resistance to quinolones include impermeability, active efflux, target modification and antibiotic neutralization. Genetic determination of quinolone resistance is generally linked to chromosomal mutations affecting the quinolone resistance-determining regions (QRDR) of DNA gyrase (GyrA and GyrB) and topoisomerase IV (ParC and ParE) \[[@B1]\]. Mutations in *gyrA*, the gene encoding for the A subunit of DNA gyrase are the most common mechanism involved in quinolone resistance among Gram negative bacteria \[[@B2]\].

In 1994, the plasmid-borne quinolone resistance genes *qnr*were identified \[[@B1]\]. The insertion sequence IS*CR1*has often been characterized in the genetic environment of *qnr*and may be involved in dissemination of the gene in Gram-negative bacteria \[[@B3]\].

Quinolone resistance was first identified in the CAR in 2003, among clinical ESBL-producing *Enterobacteriaceae*. The aim of this study was to determine the genetic mechanism of quinolone resistance of these strains isolated in the Central African Republic (CAR).

Methods
=======

Of the seventeen ESBL-producing *Enterobacteriaceae*isolated from urine, pus or stool samples between January 2003 and October 2005 at the Institut Pasteur de Bangui and previously characterized as CTX-M-15 and SHV-12, nine were resistant to ciprofloxacin (eight *Escherichia coli*and one *Klebsiella pneumoniae*) \[[@B4]\]. Seven *E.coli*strains were isolated from community patients and the two others were isolated from hospitalized patients.

Antibiotic susceptibility was determined by the diffusion disc method (Comité de l\'Antibiogramme de la Société Française de Microbiologie). The minimal inhibitory concentrations (MICs) of nalidixic acid, norfloxacin and ciprofloxacin were measured by the agar dilution method.

PCR was carried out on genomic DNA extracted with the commercial Qiagen DNA Mini Kit (Qiagen, Courtaboeuf, France) at 94 °C for 5 min, 35 cycles at 94 °C for 30 s, 55 °C for 40 s and extension at 72 °C for 60 s, followed by 72 °C for 7 min.

The ciprofloxacin-resistant isolates were screened for the *qnrA*gene by PCR with specific primers targeting IS*CR1*, 5\'-TGAAACAGAAAACAGCCAAGG-3\' (IS*CR1*qnr upper), and *qnrA*, 5\'-GCAGCACTATTACTCCAAGG-3\' (IS*CR1*qnr lower). The primers targeting IS*CR1-qnrA1*were designed with Oligo-4 software. The sequences encoding QRDR of DNA gyrase were amplified with *gyrA6*5\'-CGA CCT TGC GAG AGA AAT-3\' and *gyrA631R*5\'-GTT CCA TCA GCC CTT CAA-3\' \[[@B5]\].

All amplicons were sequenced at MWG Biotech France (<http://www.mwg-biotech.com>) and analysed with program ChromasPro 2.0 and blastN software (<http://gb-admin@ncbi.nlm.nih.gov>) (GenBank accession numbers for the sequenced IS*CR1-qnrA1*region are [JF728153](JF728153) and [JF728154](JF728154)).

All patients have given their agreement to participate in this study prior the samples collection. This study was reviewed and approved by the scientific committee board of University of Bangui in charge of the validation of scientific protocol studies in the CAR.

Results and discussion
======================

Susceptibility testing showed that all CTX-M-producing strains were resistant to nalidixic acid, norfloxacin and ciprofloxacin. The MIC of nalidixic acid and norfloxacin was 64 μg/ml and that of ciprofloxacin was 32 μg/ml for six *E. coli*and the *K. pneumoniae*strains. For two *E. coli*isolates, the MICs were higher, and PCR targeting IS*CR1-qnrA*amplified a 1050-bp fragment from these two isolates which was shown by DNA sequence analysis to be IS*CR1-qnrA1*. We could not determine the MICs values of the two *qnrA*-positive *E. coli*by the agar dilution method because they exceeded the highest concentrations of antibiotics tested in this study (32 μg/ml for ciprofloxacin and 64 μg/ml for the nalidixic acid). Other publications have shown that *qnrA*increased the MICs of quinolones by 10-fold in *Enterobacteriaceae*\[[@B6]\]. The combination of an insertion sequence IS*CR1*with *qnrA1*could ensure dissemination of quinolone resistance to both ESBL-producing and ESBL-negative *Enterobacteriaceae*. The IS*CR1*element is also capable of mobilizing *qnrA1*in multiple drug resistance regions, generally located on plasmids that mediate resistance to multiple antibiotics.

Sequence analysis of the gene portion encoding the QRDR of GyrA showed the same amino acid change in GyrA (Ser83-Leu) in all our isolates. Nucleotide mutations at codon 83 are the commonest GyrA substitutions found in quinolone-resistant *E. coli*and the serine residue is most commonly substituted by a leucine \[[@B7]\].

Conclusion
==========

We have shown that the emerging resistance of *Enterobacteriaceae*to quinolones in the CAR may be due to a topoisomerase mutation or a plasmid-borne *qnrA1*acquisition. It would be interesting to sequence the DNA gyrase *gyrB*and topoisomerase IV *parC*and *parE*genes, to screen for the other *qnr*genes (*B*and *S*) and to characterize the environment of IS*CR1-qnrA1*, which has already been found in several *sul1-*type complex integrons. The possible dissemination of IS*CR1-qnrA1*among *Enterobacteriacae*requires vigilance by bacteriology laboratories in the CAR. It will also be important to inform clinicians of the potential risk associated with prescribing quinolones and beta-lactams.
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